BRIEF-Pasithea Therapeutics Announces Positive Efficacy Data From Its Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer

Reuters09-26

Sept 26 (Reuters) - Pasithea Therapeutics Corp :

* PASITHEA THERAPEUTICS ANNOUNCES POSITIVE INITIAL SAFETY, TOLERABILITY, PHARMACOKINETIC $(PK)$, AND PRELIMINARY EFFICACY DATA FROM ITS PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED CANCER

* PASITHEA THERAPEUTICS CORP - PATIENT WITH STAGE 3 COLON CANCER ACHIEVES PROLONGED STABLE DISEASE

* PASITHEA THERAPEUTICS CORP - NO TREATMENT-RELATED ADVERSE EVENTS OR DOSE-LIMITING TOXICITIES OBSERVED

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470781782?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-26 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470781782","market":"us","top_or_hot":-1,"title":"BRIEF-Pasithea Therapeutics Announces Positive Efficacy Data From Its Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer","media":"Reuters","content":"<html><body><p>Sept 26 (Reuters) - Pasithea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Corp   :</p><p>   * PASITHEA THERAPEUTICS ANNOUNCES POSITIVE INITIAL SAFETY, TOLERABILITY, PHARMACOKINETIC <a href=\"https://laohu8.com/S/PK\">$(PK)$</a>, AND PRELIMINARY EFFICACY DATA FROM ITS PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED CANCER</p><p>   * PASITHEA THERAPEUTICS CORP - PATIENT WITH STAGE 3 COLON CANCER ACHIEVES PROLONGED STABLE DISEASE</p><p>   * PASITHEA THERAPEUTICS CORP - NO TREATMENT-RELATED ADVERSE EVENTS OR DOSE-LIMITING TOXICITIES OBSERVED</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pasithea Therapeutics Announces Positive Efficacy Data From Its Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pasithea Therapeutics Announces Positive Efficacy Data From Its Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-26 19:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 26 (Reuters) - Pasithea Therapeutics Corp   :   * PASITHEA THERAPEUTICS ANNOUNCES POSITIVE INITIAL SAFETY, TOLERABILITY, PHARMACOKINETIC $(PK)$, AND PRELIMINARY EFFICACY DATA FROM ITS PHASE 1 ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0031619046.USD","symbol_name":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2470781782","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470781782","pubTimestamp":1727348879,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 26  - Pasithea Therapeutics Corp   :   * PASITHEA THERAPEUTICS ANNOUNCES POSITIVE INITIAL SAFETY, TOLERABILITY, PHARMACOKINETIC , AND PRELIMINARY EFFICACY DATA FROM ITS PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED CANCER   * PASITHEA THERAPEUTICS CORP - PATIENT WITH STAGE 3 COLON CANCER ACHIEVES PROLONGED STABLE DISEASE   * PASITHEA THERAPEUTICS CORP - NO TREATMENT-RELATED ADVERSE EVENTS OR DOSE-LIMITING TOXICITIES OBSERVEDSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","BK4218":"酒店及度假村房地产信托","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","LENZ":"Therapeutics","AEIS":"先进能源工业公司","PK":"Park Hotels & Resorts Inc.","BK4157":"电子设备和仪器","KTTA":"Pasithea Therapeutics Corp.","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","BK4139":"生物科技","BK4181":"酒店及度假村房地产投资信托"},"translate_title":"简报-Pasithea Therapeutics宣布其Pas-004治疗晚期癌症的1期临床试验的积极疗效数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEIS":1,"KTTA":1,"LENZ":1,"PK":1},"content_text":"Sept 26 (Reuters) - Pasithea Therapeutics Corp   :   * PASITHEA THERAPEUTICS ANNOUNCES POSITIVE INITIAL SAFETY, TOLERABILITY, PHARMACOKINETIC $(PK)$, AND PRELIMINARY EFFICACY DATA FROM ITS PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED CANCER   * PASITHEA THERAPEUTICS CORP - PATIENT WITH STAGE 3 COLON CANCER ACHIEVES PROLONGED STABLE DISEASE   * PASITHEA THERAPEUTICS CORP - NO TREATMENT-RELATED ADVERSE EVENTS OR DOSE-LIMITING TOXICITIES OBSERVEDSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470781782"}